Charu Aggarwal, MD, MPH
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Penn Medicine Provider

About me

  • Physician Leader, Airways Malignancies Research
  • Director, Precision Oncology Innovation, Penn Center for Cancer Care Innovation
  • Section Chief, Head & Neck and Thoracic Cancers, Hematology-Oncology
  • Leslye M. Heisler Professor for Lung Cancer Excellence

Dr. Aggarwal specializes in the management of patients with lung cancer. Her clinical research focus is on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principal investigator for multiple clinical trials focusing on the development of targeted immunotherapy approaches.

Education and training

  • Medical School: Lady Hardinge Medical College
  • Residency: University at Buffalo, Jacobs School of Medicine and Biomedical Sciences
  • Fellowship: Fox Chase Cancer Center

What my patients think about me

Average Rating

155 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

October 2025
very professional
October 2025
she spent time with me and discussed my options for the medication i'm taking.
October 2025
reassuring
September 2025
dr aggarwal is kind and honest

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Aggarwal is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Aggarwal C, Desai A, McConnell N, Cadirov N, Gustavsen G, Agarwal A, Chehab N, Kotapati S, Patel N. Clinician Perspectives on Digital and Computational Pathology: Clinical Benefits, Concerns, and Willingness to Adopt , Diagnostics (Basel), 15: 2025,2527


Singh A, Horng H, Roshkovan L, Hershman M, Cohen EA, Aggarwal C, Carpenter EL, Katz SI, Kontos D. Development of a prognostic multiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first line immunotherapy , Sci Rep, 15: 2025,34591


Anagnostou V, Aggarwal C. Toward Response-Adaptive Therapy in Locally Advanced NSCLC: Integrating ctDNA and Radiomics for Risk Stratification , Cancer Discov, 15: 2025,1534-1536


Aggarwal C, Martinez-Marti A, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sánchez-Hernández A, Dakhil S, Camidge DR, Pillet M, Brown M, Paliompeis C, Dowson A, Cooper ZA, Kumar R, Herbst RS. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial , JAMA Netw Open, 8: 2025,e2518440


Mack PC, Redman MW, Tukachinsky H, Kozono DE, Minichiello K, Dragnev KH, Tolba KA, Neal JW, Madison RW, Waqar SN, Aggarwal C, Hirsch FR, Patel JD, Herbst RS, Chiang AC, Reckamp KL, Kelly K, Borghaei H, Gray JE, Gandara DR. Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study , Clin Cancer Res: 2025


Roy AM, Bakouny Z, Dizman N, Paul MA, Ozay ZI, Lal BM, Nawfal R, Eid M, Chehade REH, Machaalani M, Butt A, Aggarwal C, Bekaii-Saab T, Chavez-MacGregor M, Lopes G, Marshall AL, Murphy M, Owonikoko T, Xie W, Lee AI, Choueiri TK. International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings , JCO Oncol Pract: 2025


Teja Voruganti, Rosalyn Marar, Benjamin Bleiberg, Edoardo Garbo, Biagio Ricciuti, Kaushal Parikh, Charu Aggarwal Perioperative Therapy in Oncogene-Driven Non–Small Cell Lung Cancer: Current Strategies and Unanswered Questions , American Society of Clinical Oncology Educational Book, 45(3): 2025


Elghawy O, Barsouk A, Sussman JH, Bleiberg BA, Reed-Guy L, D'Avella C, Singh A, Ciunci C, Robinson K, Kosteva J, Langer C, Cohen RB, Aggarwal C, Marmarelis M, Sun L. Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC , JTO Clin Res Rep, 6: 2025,100851


Adam Barsouk, Omar Elghawy, Alex Watts, Lauren Reed-Guy, William Tompkins, Krishna Chandrasekhara, Connor B Grady, Wade Iams, Fangdi Sun, Geoffrey Liu, Devalben Patel, Jorge J Nieva, Kristen A Marrone, Vamsidhar Velcheti, Stephen V Liu, Tejas Patil, Jared Weiss, William Schwartzman, Liza C Villaruz, Amanda Hermann, Dara L Aisner, Wei-Ting Hwang, D Ross Camidge, Lova Sun, Aditi Puri Singh, Roger B Cohen, Charu Aggarwal, Corey J Langer, Melina E Marmarelis Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis , Lung Cancer, 203: 2025


Kamboj M, Kirkwood MK, Bohlke K, Gralow JR, Garrett-Mayer E, Aggarwal C. More Frequent than Annual Administration of COVID-19 Vaccination May Be Appropriate for Patients With Cancer , JCO Oncol Adv, 2: 2025,e2400107